Articles tagged with Drug Therapy
Researchers at Temple University and Johns Hopkins University found that brain-derived neurotrophic factor (BDNF) loss underlies post-myocardial infarction heart failure. BDNF levels can be replenished therapeutically, abolishing damage to heart tissue and enabling recovery.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
Researchers found that dexamethasone prevents cytokine storms in severe COVID-19 patients by inhibiting ion channels and reducing immune cell inflammation. This led to improved lung function and reduced mortality rates. The study's findings provide new insights into the mechanisms of steroid treatment in severe COVID-19.
Researchers found significant decreases in the levels of KRAS, RHOA, RAC1, and CDC42 after PCAI treatment, implicating their role in cancer progression and metastasis. These findings support the potential of PCAIs as potent agents for developing new anticancer therapeutics.
Three pre-clinical studies published in Journal of Pharmaceutical Analysis explore the molecular mechanisms underlying cardiovascular and neurological diseases, providing new avenues for therapeutic strategies.
A study published in Lasers in Surgery and Medicine suggests that light therapy, known as photobiomodulation (PBM), can improve heart function and reduce the thickness of the cardiac wall in middle-aged mice. The research also found improved neuromuscular coordination and a significant survival rate among mice with severe heart disease.
A bacterial molecule, ARBM101, has been found to efficiently lower liver copper levels in a rat model, offering a promising new therapeutic option for Wilson's disease. The treatment approach involves weekly applications followed by month-long breaks, significantly shortening the therapy period.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
Researchers from Kyushu University found that the single mechanosensitive protein VGLL3 induces fibrosis, thickening and scarring tissue. The study suggests targeting this protein could lead to new treatments against fibrosis.
Researchers at Texas A&M University have developed the first molecular therapeutic for Angelman syndrome, a devastating neurogenetic disorder. The therapy targets an evolutionarily conserved region in the UBE3A-AS transcript and has shown promising results in clinical trials.
Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Researchers studied how tumors adapt to Sotorasib and found that gene amplification and transcriptional programs lead to resistance. This knowledge can help develop targeted treatments for patients with KRAS mutations, potentially increasing survival rates.
A new study describes an optimized method for isolating and identifying nanobodies targeting SARS-CoV-2, which could lead to the development of effective therapies. The approach uses a yeast display method, reducing costs and time required for screening nanobody libraries.
A new study finds that electroconvulsive therapy (ECT), lithium, and clozapine may reduce suicide rates in adolescent men with severe mental illness. The study suggests that early intervention with medico-psychiatric treatment can lower suicide rates among late-teenage boys.
The American College of Chest Physicians released a clinical practice guideline on respiratory management for patients with neuromuscular weakness, providing evidence-based recommendations for mouthpiece ventilation and airway clearance therapies. The guideline aims to improve care for this vulnerable population.
A new study published in The Lancet found that an existing drug, sulfadoxine-pyrimethamine, protects pregnant women from sexually transmitted and reproductive tract infections. Researchers tested this drug alongside a promising new treatment, dihydroartemisinin-piperaquine, which showed unique ability to prevent malaria.
Researchers at Pusan National University have developed a novel FRET-based biosensor to detect double-strand breaks in DNA, providing real-time information on γH2AX. The sensor's sensitivity is higher than conventional immunostaining techniques, making it useful for identifying DNA damage factors and elucidating repair mechanisms.
Glaucoma researchers identify mitochondria as a key source of energy for optic nerve cells, and restoring balance can protect these cells from damage. The study suggests enhancing mitochondrial biogenesis may be a promising treatment strategy.
A phase 2 study found that ANGPTL3 inhibitor therapy reduced triglycerides by up to 70% in patients with severe hypertriglyceridemia who had previously experienced acute pancreatitis. The treatment, evicanumab-dgnb, also showed potential for cardiovascular prevention by reducing apolipoprotein B levels.
A new drug called CADD522 blocks a gene associated with driving bone cancer's spread, increasing survival rates by 50% in mice implanted with human bone cancer. The breakthrough treatment shows promise in all main bone cancer subtypes and has the potential to save lives and reduce disability.
A new study by Anglia Ruskin University found that physical activity and pelvic floor exercises can effectively increase latency time in men with premature ejaculation. The research suggests exercise as a promising non-pharmacological treatment option, potentially reducing the reliance on drugs with side effects.
A new cutaquig study found that increasing infusion volume per site resulted in a reduction of injection sites, while increasing infusion rates decreased infusion duration. The research also showed that dosing every other week demonstrated equivalency to trough levels with weekly dosing.
A new study shows that transcatheter mitral valve repair significantly reduces hospitalizations by almost 50 percent and death by nearly 30 percent in heart failure patients with severe mitral regurgitation. The procedure, using Abbott's MitraClip system, improves symptoms, reduces hospitalizations, and leads to longer survival.
Researchers developed synthetic peptide nanonets that selectively entrap bacteria, rendering them vulnerable to antimicrobial components. The nanonets displayed both trapping and killing functionalities, demonstrating potential as an anti-infective strategy.
A study published in NEJM Evidence found that seizures can be predicted at least 35 minutes before onset in patients with temporal lobe epilepsy. This breakthrough discovery has significant implications for developing more effective therapies for this common seizure disorder, which affects over 50 million people globally.
A phase 2 clinical trial shows that treating resectable stage 3 and 4 melanoma patients with pembrolizumab both before and after surgery greatly improves outcomes compared to pembrolizumab given only after surgery. This approach resulted in significantly longer event-free survival rates.
Researchers at VCU Massey Cancer Center found that simultaneous activation of Prdm16 and Smad4 proteins slows down pancreatic cancer progression. The study suggests a novel therapeutic approach to tackle this deadly disease.
Researchers have designed a compound that targets and breaks down phosphorylated p38, a posttranslationally modified protein closely associated with Alzheimer's disease. This breakthrough could provide a novel treatment for the disease and open up opportunities for future treatments of other 'undruggable' diseases.
A new review paper from Mayo Clinic outlines how obesity impacts common tests used to diagnose heart disease, such as ECG, CT scan, MRI, and echocardiogram. The study highlights the need for alternative approaches to prevent weight gain in patients with heart disease.
William L. Lombardi, MD, receives the TCT Geoffrey O. Hartzler Master Operator Award for his technical excellence and leadership in complex coronary disease therapies. He is recognized for developing novel CTO techniques and technologies to improve patient outcomes.
Scientists at Aarhus University and Berkeley Laboratory developed a method called RNA origami to design artificial RNA nanostructures. The technique allowed for the discovery of rules and mechanisms for RNA folding that will make it possible to build more ideal RNA particles for use in RNA-based medicine.
A study found that over 80% of American adults with type 2 diabetes meet the criteria to use GLP-1 RAs or SGLT2is, but only a small percentage are using them. The medications have a substantially higher cost than current first-line treatments, making it difficult for patients to access them.
A smartphone app-based cognitive behavioral therapy program lowered blood sugar levels and improved health behaviors in patients with diabetes. The study found a clear 'dose effect,' where participants completing more lessons saw greater benefits.
The ESMO Targeted Anticancer Therapies Congress 2023 features presentations on drug discovery and development for various targets, precision medicine, and early clinical trial methodology. Keynote lectures highlight novel insights in mutational signatures and epigenetic therapies.
Wilate prophylaxis showed an 84% reduction in bleeding episodes and improved quality of life in children and adults with all types of VWD. The treatment reduced the frequency of bleeding episodes by lowering the mean total annualized bleeding rate compared to on-demand treatment.
Researchers have created twin-bioengine yeast micro/nanorobots that can autonomously navigate to inflamed sites in the gut, providing precise delivery of therapeutics via enzyme-macrophage switching. The robots effectively penetrate intestinal mucus barriers and increase drug accumulation at diseased sites.
Researchers from Tokyo Medical and Dental University investigated the safety of anti-VEGF drug Aflibercept in a cell culture model exposed to HTLV-1. The study found that treatment did not increase pro-viral load or proliferation of RPE cells, suggesting potential for intraocular use.
A new analysis of COVID-19 patient data reveals that remdesivir significantly lowers mortality in unvaccinated patients with conventional oxygen support. The study found no evidence of varying treatment effects based on age, comorbidities, or inflammation levels.
Researchers found that fasudil reversed reduced pyramidal neuron density and cognitive dysfunction associated with methamphetamine treatment in mice with ARHGAP10 gene mutations. Fasudil also restored the density of pyramidal neurons, improving visual discrimination tests performance.
Scientists have successfully corrected limb length in a mouse model of FZD2-associated autosomal dominant Robinow Syndrome, a genetic disorder that affects skeletal growth and development. The treatment involves using a drug that stimulates the signalling pathway, resulting in significantly longer limbs than untreated mice.
Studies elucidate key aspects of traditional Chinese compounds and modern cancer therapeutics, highlighting the efficacy of R. serra in treating colitis and identifying active components of Gan Cao in treating pneumonia. A new radiolabeled antibody-based probe for detecting PD-L1 expression in cancers also provides a novel approach to ...
A recent study published in Radiology found that thrombectomy is a safe and feasible treatment option for patients with primary isolated anterior cerebral artery medium vessel occlusions. The procedure showed similar outcomes to medical treatment in terms of early and long-term functional outcomes, mortality rates, and safety.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified CD70 as a novel therapeutic target for eliminating drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer. CD70 targeting strategies showed significant anti-tumor activity, eliminating resistant cells in laboratory models.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
Scientists have discovered that wrinkles in the cellular nucleus may be involved in common metabolic diseases such as diabetes and fatty liver disease. The new findings suggest that targeting these wrinkles could lead to novel treatments for non-alcoholic fatty liver disease, which affects 40% of people over age 70.
Researchers at Helmholtz-Zentrum Dresden-Rossendorf developed a new strategy to increase target molecules for radionuclide therapy in pheochromocytoma tumors, delaying tumor growth. The combination of valproic acid and decitabine prior to therapy doubled the radiation dose absorbed by the tumor.
Researchers found associations between cancer treatments and accumulated mutations in blood cells, a sign of accelerated aging called clonal hematopoiesis. This accumulation increases the risk of blood cancer and death in long-term childhood cancer survivors.
The work group reframed what is clinically meaningful to slow Alzheimer's disease progression, including the need for combination therapies and realistic expectations of benefits and risks. Slowing brain deterioration by four to six months in early stages may preserve function, leading to meaningful outcomes for patients and families.
A new American Heart Association scientific statement outlines ideal foundational requirements for stroke program development and growth. The guidelines aim to minimize inconsistencies and improve services provided by certified stroke centers across the U.S., emphasizing leadership, personnel resources, and quality improvement.
A study by University of Gothenburg researchers found a significant association between methotrexate use and an increased risk of basal cell carcinoma, squamous cell carcinoma, and cutaneous malignant melanoma. The study suggests that higher doses of methotrexate may increase the risk of SCC and BCC, while no dose-response relationship...
An updated Cochrane review found no effect of vitamin D supplements on reducing the risk of asthma attacks or improving control of asthma symptoms in children and adults. The review analyzed data from 20 randomized controlled trials involving over 2,200 people with mild to moderate asthma.
A new study found that Black and Hispanic stroke survivors in the US are less likely to receive treatment for common complications, despite improved overall stroke survival rates. Researchers analyzed electronic health records from 2002 to 2022 and matched patients based on 41 factors to minimize biases.
Researchers found that patients treated with butylphthalide experienced milder neurological symptoms and better functioning at three months after a stroke compared to those who received a placebo. The study suggests potential benefits of this celery seed-derived medication in treating ischemic strokes.
Researchers found that pacing patients at faster heart rates improved quality of life, physical activity, and reduced atrial fibrillation. This new treatment approach shows promise in treating heart failure with a stiff heart muscle.
A genomic study of the Seattle 2017-2022 Shigella outbreak revealed its origin as international travelers from areas where Shigella was common. The study also found that multi-drug resistant Shigella has become a growing global health concern, primarily affecting men who have sex with men and those experiencing homelessness.
A novel form of chemoimmunotherapy has been proven to be a promising treatment for canine cancer, extending the lives of terminally ill dogs. The therapy uses modified Mesenchymal Stem Cells carrying a potent 'kill-switch' that induces anti-cancer immunity and improves quality of life.
Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.
Researchers from TIBI have developed an advanced electronic skin patch that provides simultaneous, continuous monitoring of multiple bodily parameters. The new E-skin patch offers enhanced flexibility, thermal cooling abilities, and fluid absorption over conventional substrates while demonstrating excellent biocompatibility and biodegr...
Researchers from UTSA and UT Health San Antonio are developing compounds that target the estrogen receptor-beta, which suppresses cancer growth. The goal is to identify a novel ER-beta agonist with potential as a therapeutic strategy for treating GBM in patients.